The Oncology Institute, Inc. TOI Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Other Operating Income by Business | ||||||
| Clinical trials & other | $813K-54.2% | $772K-61.3% | $474K-69.6% | $1.22M-10.6% | $1.77M-15.0% | |
| Patient services | $4.25M-5.9% | $5.76M+146% | $4.17M+24.2% | $3.26M-31.0% | $4.52M+162% | |
| Specialty pharmacy | $16.8M+78.7% | —— | —— | —— | $9.4M+31.6% | |
| Total operating revenue by Product | ||||||
| Capitated revenue | $26.93M+53.9% | $23.57M+34.6% | $20.57M+38.9% | $18.84M+0.8% | $17.5M-1.0% | |
| Clinical trials & other | $813K-60.2% | $705K-71.4% | $474K-75.6% | $1.34M-20.2% | $2.05M-19.3% | |
| FFS revenue | $32.16M-9.6% | $36.27M+10.9% | $39.62M+13.4% | $37.05M+9.7% | $35.57M+2.3% | |
| Patient services | $59.09M+11.3% | $59.84M+19.2% | $60.2M+21.0% | $55.89M+6.5% | $53.07M+1.2% | |
| Specialty Pharmacy | $87.54M+77.6% | —— | —— | —— | $49.29M+9.6% | |
| Number of lease modifications by Geography | ||||||
| CALIFORNIA | 1— | —— | —— | —— | —— | |
| FLORIDA | 4— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does The Oncology Institute, Inc. break its business down?
- The Oncology Institute, Inc. (TOI) reports other operating income by business across 3 parts — Clinical trials & other, Patient services and Specialty pharmacy. Each is extracted from the segment footnotes and tracked over time.
- Where does The Oncology Institute, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in The Oncology Institute, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
